vs
Protalix BioTherapeutics, Inc.（PLX）与Rocky Mountain Chocolate Factory, Inc.（RMCF）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是Rocky Mountain Chocolate Factory, Inc.的1.2倍（$9.1M vs $7.5M），Rocky Mountain Chocolate Factory, Inc.净利率更高（-2.1% vs -60.3%，领先58.3%），Rocky Mountain Chocolate Factory, Inc.同比增速更快（-4.4% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $-1.3M），过去两年Rocky Mountain Chocolate Factory, Inc.的营收复合增速更高（1.9% vs -6.7%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
落基山巧克力厂是美国知名巧克力企业，同时开展国际特许经营业务，集糖果生产与零售运营于一体，总部位于美国科罗拉多州杜兰戈，除美国本土门店外，在巴拿马、菲律宾也设有经营网点。
PLX vs RMCF — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $7.5M |
| 净利润 | $-5.5M | $-155.0K |
| 毛利率 | 49.4% | 34.0% |
| 营业利润率 | -51.1% | 1.1% |
| 净利率 | -60.3% | -2.1% |
| 营收同比 | -49.9% | -4.4% |
| 净利润同比 | -184.8% | 81.7% |
| 每股收益（稀释后） | $-0.06 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $9.1M | $7.5M | ||
| Q3 25 | $17.9M | $6.8M | ||
| Q2 25 | $15.7M | $6.4M | ||
| Q1 25 | $10.1M | $8.9M | ||
| Q4 24 | $18.2M | $7.9M | ||
| Q3 24 | $18.0M | $6.4M | ||
| Q2 24 | $13.5M | $6.4M | ||
| Q1 24 | — | $7.3M |
| Q4 25 | $-5.5M | $-155.0K | ||
| Q3 25 | $2.4M | $-662.0K | ||
| Q2 25 | $164.0K | $-324.0K | ||
| Q1 25 | $-3.6M | $-2.9M | ||
| Q4 24 | $6.5M | $-847.0K | ||
| Q3 24 | $3.2M | $-722.0K | ||
| Q2 24 | $-2.2M | $-1.7M | ||
| Q1 24 | — | $-1.6M |
| Q4 25 | 49.4% | 34.0% | ||
| Q3 25 | 53.4% | 23.6% | ||
| Q2 25 | 62.5% | 31.1% | ||
| Q1 25 | 19.1% | 10.8% | ||
| Q4 24 | 78.7% | 23.4% | ||
| Q3 24 | 53.4% | 31.8% | ||
| Q2 24 | 29.8% | 12.8% | ||
| Q1 24 | — | 24.3% |
| Q4 25 | -51.1% | 1.1% | ||
| Q3 25 | 11.9% | -7.0% | ||
| Q2 25 | 7.5% | -2.3% | ||
| Q1 25 | -41.0% | -30.3% | ||
| Q4 24 | 39.6% | -8.9% | ||
| Q3 24 | 22.2% | -14.3% | ||
| Q2 24 | -18.0% | -25.4% | ||
| Q1 24 | — | -21.7% |
| Q4 25 | -60.3% | -2.1% | ||
| Q3 25 | 13.2% | -9.7% | ||
| Q2 25 | 1.0% | -5.1% | ||
| Q1 25 | -35.8% | -32.5% | ||
| Q4 24 | 35.6% | -10.7% | ||
| Q3 24 | 18.0% | -11.3% | ||
| Q2 24 | -16.4% | -25.9% | ||
| Q1 24 | — | -21.9% |
| Q4 25 | $-0.06 | $-0.02 | ||
| Q3 25 | $0.03 | $-0.09 | ||
| Q2 25 | $0.00 | $-0.04 | ||
| Q1 25 | $-0.05 | $-0.38 | ||
| Q4 24 | $0.10 | $-0.11 | ||
| Q3 24 | $0.03 | $-0.11 | ||
| Q2 24 | $-0.03 | $-0.26 | ||
| Q1 24 | — | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | $641.0K |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.2M | $6.0M |
| 总资产 | $82.3M | $20.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $14.7M | $641.0K | ||
| Q3 25 | $13.6M | $2.0M | ||
| Q2 25 | $17.9M | $893.0K | ||
| Q1 25 | $19.5M | $720.0K | ||
| Q4 24 | $19.8M | $1.1M | ||
| Q3 24 | $27.4M | $973.0K | ||
| Q2 24 | $23.4M | $637.0K | ||
| Q1 24 | — | $2.1M |
| Q4 25 | $48.2M | $6.0M | ||
| Q3 25 | $52.9M | $6.1M | ||
| Q2 25 | $49.9M | $6.7M | ||
| Q1 25 | $45.2M | $7.0M | ||
| Q4 24 | $43.2M | $9.8M | ||
| Q3 24 | $32.4M | $10.5M | ||
| Q2 24 | $28.6M | $9.0M | ||
| Q1 24 | — | $10.6M |
| Q4 25 | $82.3M | $20.7M | ||
| Q3 25 | $82.3M | $22.3M | ||
| Q2 25 | $78.5M | $20.1M | ||
| Q1 25 | $73.9M | $21.2M | ||
| Q4 24 | $73.4M | $21.6M | ||
| Q3 24 | $61.6M | $21.1M | ||
| Q2 24 | $91.5M | $19.0M | ||
| Q1 24 | — | $20.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | $1.6M | $-1.3M |
| 自由现金流率自由现金流/营收 | 17.8% | -16.9% |
| 资本支出强度资本支出/营收 | 4.4% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-13.6M | — |
8季度趋势，按日历期对齐
| Q4 25 | $2.0M | $-1.2M | ||
| Q3 25 | $-3.7M | $-488.0K | ||
| Q2 25 | $-5.2M | $350.0K | ||
| Q1 25 | $-5.1M | $1.2M | ||
| Q4 24 | $4.0M | $-2.1M | ||
| Q3 24 | $4.1M | $-3.5M | ||
| Q2 24 | $-3.6M | $-2.2M | ||
| Q1 24 | — | $129.0K |
| Q4 25 | $1.6M | $-1.3M | ||
| Q3 25 | $-4.2M | $-544.0K | ||
| Q2 25 | $-5.7M | $182.0K | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.0M | $-4.6M | ||
| Q2 24 | $-3.8M | $-2.6M | ||
| Q1 24 | — | $-352.3K |
| Q4 25 | 17.8% | -16.9% | ||
| Q3 25 | -23.7% | -8.0% | ||
| Q2 25 | -36.2% | 2.9% | ||
| Q1 25 | -53.0% | — | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | -72.6% | ||
| Q2 24 | -28.1% | -40.2% | ||
| Q1 24 | — | -4.9% |
| Q4 25 | 4.4% | 0.5% | ||
| Q3 25 | 2.8% | 0.8% | ||
| Q2 25 | 2.8% | 2.6% | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.5% | 17.5% | ||
| Q2 24 | 1.3% | 6.5% | ||
| Q1 24 | — | 6.6% |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
RMCF
| Manufacturing | $5.9M | 78% |
| Transferred At Point In Time | $1.2M | 16% |
| Other | $414.0K | 5% |
